Theranexus chosen by non-profit to advance Batten disease drug
French CNS specialist Theranexus (Euronext: ALTHX), which is developing drugs modulating the interaction between neurons and glial cells, has announced an agreement in principle with Beyond Batten Disease Foundation (BBDF).
The Texas-based non-profit organization has funded research to identify and validate BBDF 101 for the treatment of juvenile Batten disease, and now it will jointly lead the clinical development program in the USA with Theranexus, in the hope of securing regulatory approval.
Theranexus has a six-month exclusivity period to reach a final agreement and, if it does so, will have an exclusive worldwide license for commercial use of the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze